{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.2","upperLimit":"48.7","value":"28.6"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"38.3","value":"12.5"},{"groupId":"OG002","lowerLimit":"0.4","upperLimit":"57.9","value":"14.3"},{"groupId":"OG003","lowerLimit":"8.5","upperLimit":"23.1","value":"14.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"102"}],"units":"Participants"}],"description":"CRR is the percentage of patients with at least one visit response of CR based on CT and/or PET scans evaluated by investigator per Lugano criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Group A: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG000","title":"AZD4205 Group A"},{"description":"Group B: Open label AZD4205 at 250 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG001","title":"AZD4205 Group B"},{"description":"Group C: Open label AZD4205 at 150 mg, once daily (Phase 1)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG002","title":"AZD4205 Group C"},{"description":"Group D: Open label AZD4205 at 150 mg (RP2D), once daily (Phase 2)\n\nAZD4205: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions","id":"OG003","title":"AZD4205 Group D"}],"paramType":"NUMBER","populationDescription":"Part A: Evaluable for Response Set Part B: Evaluable for CT-based Response Set","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Part A and Part B: CRR Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}